Abstract
Cell penetrating peptides (CPPs) are 9-35mer cationic and/or amphipathic peptides that are rapidly internalized across cell membranes. Importantly, they can be linked to a variety of cargo, including anti-cancer therapeutics, making CPPs an efficient, effective and non-toxic mechanism for drug delivery. In this review, we discuss a number of CPP conjugated therapies (CTTs) that are either patented are in the progress of patenting, and show strong promise for clinical efficacy. The CTTs discussed here target a number of different processes specific to cancer progression, including proliferation, survival and migration. In addition, many of these CTTs also increase sensitivity to current anti-cancer therapy modalities, including radiation and other DNA damaging chemotherapies, thereby decreasing the toxic dosage required for effective treatment. Mechanistically, these CTTs function in a dominant-negative manner by blocking tumorspecific protein-protein interactions with the CPP-conjugated peptide or protein. The treatment of both cell lines and mouse models demonstrates that this method of molecular targeting results in equal if not greater efficacy than current standards of care, including DNA damaging agents and topoisomerase inhibitors. For the treatment of invasive carcinoma, these CTTs have significant clinical potential to deliver highly targeted therapies without sacrificing the patients quality of life.
Keywords: Cell penetrating peptides, protein transduction domain, Tat, targeted therapies, patent
Recent Patents on Anti-Cancer Drug Discovery
Title: Anti-Cancer Therapies that Utilize Cell Penetrating Peptides
Volume: 5 Issue: 2
Author(s): Benjamin G. Bitler and Joyce A. Schroeder
Affiliation:
Keywords: Cell penetrating peptides, protein transduction domain, Tat, targeted therapies, patent
Abstract: Cell penetrating peptides (CPPs) are 9-35mer cationic and/or amphipathic peptides that are rapidly internalized across cell membranes. Importantly, they can be linked to a variety of cargo, including anti-cancer therapeutics, making CPPs an efficient, effective and non-toxic mechanism for drug delivery. In this review, we discuss a number of CPP conjugated therapies (CTTs) that are either patented are in the progress of patenting, and show strong promise for clinical efficacy. The CTTs discussed here target a number of different processes specific to cancer progression, including proliferation, survival and migration. In addition, many of these CTTs also increase sensitivity to current anti-cancer therapy modalities, including radiation and other DNA damaging chemotherapies, thereby decreasing the toxic dosage required for effective treatment. Mechanistically, these CTTs function in a dominant-negative manner by blocking tumorspecific protein-protein interactions with the CPP-conjugated peptide or protein. The treatment of both cell lines and mouse models demonstrates that this method of molecular targeting results in equal if not greater efficacy than current standards of care, including DNA damaging agents and topoisomerase inhibitors. For the treatment of invasive carcinoma, these CTTs have significant clinical potential to deliver highly targeted therapies without sacrificing the patients quality of life.
Export Options
About this article
Cite this article as:
Bitler G. Benjamin and Schroeder A. Joyce, Anti-Cancer Therapies that Utilize Cell Penetrating Peptides, Recent Patents on Anti-Cancer Drug Discovery 2010; 5 (2) . https://dx.doi.org/10.2174/157489210790936252
DOI https://dx.doi.org/10.2174/157489210790936252 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Efficient Prediction of HPV Genotypes from Partial Coding Sequences by Chaos Game Representation and Fuzzy k-Nearest Neighbor Technique
Current Bioinformatics Neurocysticercosis: The Enigmatic Disease
Central Nervous System Agents in Medicinal Chemistry Women’s Ginseng (Angelica sinensis): An Ethnopharmacological Dossier
Current Traditional Medicine FDG-PET/CT and SPECT/CT in Oncology
Current Medical Imaging Calix[n]arenes as Goldmines for the Development of Chemical Entities of Pharmaceutical Interest
Current Pharmaceutical Design Natural Monoclonal Antibodies and Cancer
Recent Patents on Anti-Cancer Drug Discovery Systemic Delivery of Curcumin: 21st Century Solutions for an Ancient Conundrum
Current Drug Discovery Technologies Some Recent Synthetic Development on Compounds with Potent Activities on Hormone-sensitive Breast Cancers
Current Organic Chemistry Synthesis and Biological Activity of Pyrazolo[4,3-c]heterocyclic Derivatives: A Mini Review
Mini-Reviews in Organic Chemistry Cellular and Physiological Effects of Ganoderma lucidum (Reishi)
Mini-Reviews in Medicinal Chemistry Tetrazole Derivatives as Promising Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry A Facile Synthesis and Anticancer Activity Evaluation of Spiro Analogues of Benzothiazolylchromeno/pyrano Derivatives
Letters in Drug Design & Discovery Computational Analysis of Dynamical Fluctuations of Oncoprotein E7 (HPV 16) for the Hot Spot Residue Identification Using Elastic Network Model
Letters in Drug Design & Discovery Poly(ADP-ribose) Polymerase-1 Inhibitor 3-Aminobenzamide Enhances Apoptosis Induction by Platinum Complexes in Cisplatin-Resistant Tumor Cells
Medicinal Chemistry Role of Metabolic Enzymes P450 (CYP) on Activating Procarcinogen and their Polymorphisms on the Risk of Cancers
Current Drug Metabolism Synthesis, Biological Activity of Thiazolidinones Bearing Indoline Moiety and Isatin Based Hybrids
Mini-Reviews in Organic Chemistry The Emerging Role of EMT-related lncRNAs in Therapy Resistance and their Applications as Biomarkers
Current Medicinal Chemistry Bone Regeneration: Microparticulate and Biomimetic Strategies
Current Tissue Engineering (Discontinued) Can Breast Cancer Stem Cells Evade the Immune System?
Current Medicinal Chemistry Targeting Ion Channels for New Strategies in Cancer Diagnosis and Therapy
Current Clinical Pharmacology